MedPage Today on MSN

Could This Be the First Disease-Modifying Drug in Bronchiectasis?

C HICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic ...
The American Journal of Managed Care

Integrating Brensocatib and CT Scans Into NCF Bronchiectasis Management: James Chalmers, MBChC, PhD

The use of CT scans is moving beyond a simple diagnostic tool for non–cystic fibrosis bronchiectasis to become a practical ...
pharmaphorum

CHMP backs first drug for lung disease bronchiectasis

Insmed's DPP1 inhibitor Brinsupri (brensocatib) has been recommended by the CHMP for the treatment of patients aged 12 and ...
Medscape

Suspected Bronchiectasis Linked to Increased Risk for Death in Smokers With Normal Lung Function and COPD

Suspected bronchiectasis, defined as a combination of clinical symptoms and radiologic evidence of abnormal airways, is associated with a 15% higher risk for death in adults with normal spirometry, ...

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis ...
The American Journal of Managed Care

Brensocatib Reduced Symptom Burden, Neutrophil Serine Proteases Activity in Bronchiectasis

Brensocatib effectively reduces NSP activity in bronchiectasis patients, with greater reductions observed in the 25-mg dose group compared to the 10-mg group.
Hosted on MSN

British scientists find treatment for disease that contributed to Pope Francis’s death

British scientists have found the first-ever treatment for bronchiectasis, the disease Pope Francis was hospitalized with in the weeks prior to his death, The Telegraph reported. Francis suffered from ...
Medscape

5-Year Registry Outcomes for Bronchiectasis, NTM Nearly Identical

NEW YORK, New York — Despite significant baseline differences, the disease progression and the outcomes at 5 years are similar in those with nontuberculous mycobacteria (NTM) infection relative to ...
Pulmonology Advisor

Brensocatib Beneficial in Bronchiectasis Regardless of Patient’s COPD Status

Brensocatib was associated with decreased exacerbation rates in patients with non-CF bronchiectasis, even in those with ...
Monthly Prescribing Reference

Brensocatib Reduces the Rate of Pulmonary Exacerbations in Bronchiectasis

Insmed plans to file a New Drug Application with the Food and Drug Administration in the fourth quarter of 2024. Treatment with brensocatib reduced the frequency of pulmonary exacerbations in patients ...
Pharmabiz

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis

EMA committee recommends approval of Insmed’s Brinsupri to treat non-cystic fibrosis bronchiectasis: Bridgewater, New Jersey Monday, October 20, 2025, 15:00 Hrs [IST] Insmed Inc ...
Healio

Suspected bronchiectasis linked to high mortality risk regardless of lung function

Please provide your email address to receive an email when new articles are posted on . Adults with a long-term smoking history suspected to have bronchiectasis faced an elevated mortality risk ...